Brokers Offer Predictions for Shattuck Labs FY2026 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Equities researchers at HC Wainwright dropped their FY2026 EPS estimates for shares of Shattuck Labs in a research note issued on Thursday, November 5th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.55) for the year, down from their prior estimate of ($0.42). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at ($0.70) EPS.

Several other equities analysts have also recently weighed in on STTK. Wall Street Zen cut Shattuck Labs from a “hold” rating to a “sell” rating in a research report on Saturday. TD Cowen raised Shattuck Labs to a “strong-buy” rating in a research report on Monday, August 24th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Shattuck Labs in a research report on Thursday. Wedbush upped their price target on Shattuck Labs from $11.00 to $14.00 and gave the stock an “outperform” rating in a report on Friday, October 2nd. Finally, JPMorgan Chase & Co. initiated coverage on Shattuck Labs in a research report on Friday, July 24th. They issued an “overweight” rating and a $10.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Shattuck Labs currently has a consensus rating of “Buy” and an average target price of $13.70.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK opened at $4.99 on Monday. The company has a market cap of $500.80 million, a P/E ratio of -9.78 and a beta of 1.21. The stock’s 50-day moving average is $5.96 and its 200-day moving average is $6.03. Shattuck Labs has a 52-week low of $1.72 and a 52-week high of $8.33.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03).

Hedge Funds Weigh In On Shattuck Labs

Several large investors have recently added to or reduced their stakes in STTK. Legal & General Group Plc bought a new stake in shares of Shattuck Labs in the 2nd quarter worth approximately $41,000. ProShare Advisors LLC bought a new stake in shares of Shattuck Labs during the third quarter valued at approximately $70,000. State of Wyoming acquired a new position in shares of Shattuck Labs in the second quarter valued at $151,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Shattuck Labs by 74.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 25,600 shares of the company’s stock valued at $167,000 after purchasing an additional 10,959 shares in the last quarter. Finally, Profund Advisors LLC acquired a new position in shares of Shattuck Labs in the third quarter valued at $195,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.